Ethereum treasury company Propanc Biopharma has reached a strategic financing agreement with Hexstone Capital for up to $100 million

ChainCatcher news, biopharmaceutical company Propanc Biopharma, which adopts an Ethereum treasury strategy, announced a strategic financing agreement with family office Hexstone Capital for up to $100 million. Propanc CEO James Nathanielsz stated that this financing will accelerate the development of the company's clinical pipeline and aims to increase the value of its digital asset portfolio to $100 million or more within the next 12 months.

Hexstone Capital has previously invested in several companies with digital asset portfolios, involving various digital assets such as BTC, ETH, SOL, and DOGE. Earlier news reported that in early September, Propanc Biopharma announced plans to acquire $100 million in Ethereum.